Second opinion changes diagnosis from incurable to curable cancer

The Journal of Clinical Oncology reports the case of a woman diagnosed with advanced, incurable lung cancer, whose disease was in fact early stage, curable lung cancer with additional lung lesions due to a rare antibiotic side effect. When her primary lung tumor was surgically removed, and the antibiotic stopped, the 62-year-old woman recovered and may now be cured.

"In a good example of collaboration with our local oncology community, my colleague wanted a second opinion to ensure his patient got the best possible treatment plan established from the get-go, said Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at the University of Colorado Cancer Center and the senior author of the study. "Initially, they were probably looking for some kind of molecular profiling and possibly a novel drug or combination of drugs in a clinical trial. Instead, through some great teamwork, we were able to reveal something unexpected and radically change her prognosis."

The patient, a former smoker, visited her doctor with a cough, fatigue and weight loss. Her scans revealed a dominant mass in her right lung with multiple smaller nodules and infiltrates throughout both lungs. The biggest mass was biopsied and showed non-small cell lung cancer. Because the disease appeared throughout both lungs, the patient appeared to have advanced stage or metastatic lung cancer, a condition which nationally, is associated with a 5-year survival rate of less than 3 percent.

"But then Eiko Browning, MD, our outstanding senior trainee in oncology, began to notice a series of clues that something else was happening," said Camidge.

First, there were changes in the patient's blood tests showing some damage to the liver, but there were no signs of cancer in the liver. Second, the CU team noticed she also had a long history of urinary tract infections treated with the antibiotic, nitrofurantoin.

Nicole Restauri, MD, the CU radiologist reviewing the scans, then pointed out the little known fact that about one in 100,000 women who take nitrofurantoin experience unusual side effects, including liver and . Consequently, Camidge and colleagues hypothesized that toxicity due to the antibiotic, and not spread of the lung cancer, could have created the appearance of widespread lung abnormalities. To prove this, they stopped the antibiotic and simply repeated the scans and blood tests a few weeks later. When the liver tests returned to normal and everything except the known lung cancer had disappeared from her scans, the team was able to change her diagnosis from incurable, metastatic lung cancer to early stage, curable .

"The prompt, correct diagnosis dramatically changed this patient's care," Camidge said. "Instead of suggesting that this patient undergo standard chemotherapy or treatment in clinical trials, we simply performed surgery. She is now in long-term follow-up care with no evidence of cancer recurrence to date."

Camidge goes on to say, "This is a great example of a community oncologist pushing for the best treatment plan for their patient by actively seeking out a second opinion before commencing treatment. While not always this dramatic, this certainly illustrates the full extent of what a second opinion from an expert multi-disciplinary team can accomplish. When you are dealing with something as serious as , getting another set of eyes to look things over early on can sometimes pay huge dividends."

More information: Paper: jco.ascopubs.org/content/early… 1.6930.full.pdf+html

add to favorites email to friend print save as pdf

Related Stories

Benefit of targeted lung cancer therapy confirmed

Jun 03, 2011

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

21 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.